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Childhood-onset mitochondrial encephalomyopathies are usually severe, relentlessly progressive conditions that have a fatal out-
come. However, a puzzling infantile disorder, long known as ‘benign cytochrome c oxidase deﬁciency myopathy’ is an exception
because it shows spontaneous recovery if infants survive the ﬁrst months of life. Current investigations cannot distinguish those
with a good prognosis from those with terminal disease, making it very difﬁcult to decide when to continue intensive supportive
care. Here we deﬁne the principal molecular basis of the disorder by identifying a maternally inherited, homoplasmic m.14674T4C
mt-tRNA
Glu mutation in 17 patients from 12 families. Our results provide functional evidence for the pathogenicity of the mutation
and show that tissue-speciﬁc mechanisms downstream of tRNA
Glu may explain the spontaneous recovery. This study provides the
rationale for a simple genetic test to identify infants with mitochondrial myopathy and good prognosis.
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Introduction
Mitochondrial diseases are a large and clinically heterogeneous
group of disorders that result from deﬁciencies in cellular energy
production and have an estimated birth incidence of 1:5000,
making them among the most common inherited metabolic dis-
eases (Schaefer et al., 2008). More than 200 mitochondrial DNA
(mtDNA) point mutations have been identiﬁed as primary causes
of mitochondrial disease, predominantly in mitochondrial transfer
RNA (mt-tRNA) genes (DiMauro and Hirano, 2005; Taylor and
Turnbull, 2005; Pereira et al., 2009). In addition, mutations in
nuclear genes may also affect single or multiple respiratory chain
(RC) enzymes, causing diseases inherited as Mendelian traits
(DiMauro and Hirano, 2005). Affected children often suffer from
multisystem disorders and die in childhood. The underlying genetic
defect in many patients remains unknown and there are no effec-
tive treatments (Shoubridge, 2001; Debray et al., 2007). However,
a puzzling clinical syndrome, initially termed ‘benign infantile mito-
chondrial myopathy due to reversible cytochrome c oxidase (COX)
deﬁciency’ stands out by showing complete (or almost complete)
spontaneous recovery (DiMauro et al., 1981). Affected children
uniformly present with severe muscle weakness and hypotonia in
the ﬁrst days or weeks of life and often require assisted ventila-
tion. However, they improve spontaneously between 5 and
20 months of age and are usually normal by 2 or 3 years of
age (DiMauro et al., 1981, 1983; Roodhooft et al., 1986;
Zeviani et al., 1987; Nonaka et al., 1988; Tritschler et al., 1991;
Salo et al., 1992; Wada et al., 1996). Although potentially benign,
this myopathy is life-threatening in the ﬁrst months of life and
patients require vigorous life-sustaining measures. Muscle biopsies
taken in the neonatal period are essentially identical to those of
children with irreversible and fatal COX deﬁciency. There are
numerous ragged-red ﬁbres (RRF) indicative of mitochondrial
accumulation and the histochemical reaction for COX activity is
absent in virtually all ﬁbres, although present in spindles and
intramuscular blood vessels, emphasizing that skeletal muscle is
the only affected tissue (Tritschler et al., 1991). However, biopsies
taken at later times show no RRF and increasing numbers of
COX-positive ﬁbres, in parallel with the clinical and biochemical
recovery (Salo et al., 1992; Wada et al., 1996).
Despite thorough investigations, until now no speciﬁc test was
available to distinguish children with the reversible disease from
those with the lethal COX-deﬁciency. It was speculated that the
defect might involve a nuclear-encoded COX subunit that is not
only tissue speciﬁc, but also developmentally regulated (Tritschler
et al., 1991). Mutations of a foetal or neonatal muscle isoform
would be overcome on expression of the mature isoform, as seen
for example, in the rare congenital myasthenic Escobar syndrome
(Hoffmann et al., 2006). However, sequencing of the genes
encoding the obvious candidates, COXVIa and COXVIIa, did not
reveal any mutations (Tritschler et al., 1991). Early differential
diagnosis between fatal and benign mitochondrial myopathies is
of critical importance for prognosis and management of these
infants, because the benign form is initially life threatening but
ultimately reversible. Here, we deﬁne a simple molecular test
that will identify children with reversible COX deﬁciency.
Supportive care should not be withdrawn from these children
early in life.
Materials and methods
Patients
The study included 17 patients with the clinical phenotype of rever-
sible COX deﬁciency (Table 1). All patients were white Caucasians, but
from different ethnic groups (American, Swedish, German, Brazilian
and Italian).
Muscle histology and biochemistry
Muscle histology was performed by standard methods. Activities of RC
complexes I–IV were determined in skeletal muscle and cultured cells
(myoblasts and ﬁbroblasts) as described (Fischer et al., 1986; Tulinius
et al., 1991).
Molecular genetic studies
Sequencing of the mtDNA, Southern blot and long-range PCR for
mtDNA rearrangements and real-time PCR for assessment of mtDNA
copy numbers were carried out using standard methods.
Levels of m.14674T4C mutant mtDNA were assessed by last hot
cycle PCR/RFLP. DNA samples were processed as described by Taylor
et al. (2003) with the following modiﬁcations. PCR ampliﬁcations were
performed using the forward mismatch primer L14651 (nt positions
14651–14673) 50-AACAGAAACAAAGCATACACCAT-30 (mismatch
base shown in bold) and the M13-tagged reverse primer M13-
H14810 (nt positions 14810–14791) 50-CAGGAAACAGCTATGACC
GGAGGTCGATGAATGAGTGG-30 with an annealing temperature
of 60 C, generating a 182-bp fragment that encompasses
the m.14674T4C mutation site. Equal amounts of (alpha-
32P)-deoxycytidinetriphosphate-labelled PCR products were then
digested with 10U BccI (New England Biolabs, Hitchin, UK). Wild-
type amplicons contain a single BccI recognition site and on digestion,
two fragments of 108 and 74bp are generated. In PCR products har-
bouring the m.14674T4C mutation, the mismatch primer creates an
additional BccI site, producing three fragments of 108, 46 and 28bp.
High-resolution northern blot analysis
Total RNA from skeletal muscle and from 1 10
6 to 2 10
6 cultured
primary ﬁbroblasts, myoblast and differentiated myoblast (myotubes)
lines was extracted using Trizol reagent (Life Technologies, Paisley,
UK) according to the manufacturer’s instructions. High-resolution
northern blot analysis of total RNA (1mg) was performed as previously
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Leu(UUR) probe
was generated using the forward primer L3200 (positions 3200–3219)
50-TATACCCACACCCACCCAAG-30 and reverse primer H3353 (posi-
tions 3353–3334) 50-GCGATTAGAATGGGTACAAT-30. The human
mt-tRNA
Glu probe was generated using the forward primer L14635
(positions 14810–14791) 50-TACTAAACCCACACTCAACAG-30 and
reverse primer H14810 (positions 14810–14791) 50-GGAGGTCG
ATGAATGAGTGG-30. The radioactive signal for the mt-tRNA
Glu
probe was normalized to that of the tRNA
Leu(UUR) probe for each
sample.
Immunoblotting
Aliquots of 10–20mg protein from skeletal muscle or cell homogenates
were loaded on 15% SDS–polyacrylamide gels and tested with anti-
bodies recognizing COXII, CI-20/NDUFB8, CII-70kDa (Mitosciences,
Eugene, Oregon, USA), COXI and Porin (Molecular Probes, Eugene,
Oregon, USA) according to the supplier’s recommendations.
Cell culture experiments
Human primary ﬁbroblasts and myoblasts were obtained from Patients
7 and 14. Control cells were requested from the Muscle Tissue Culture
Collection (Friedrich-Baur Institute Munich). Muscle cells were grown
in skeletal muscle growth medium (SGM; PromoCell, Heidelberg,
Germany), supplemented with 4mM L-glutamine and 10% foetal
bovine serum (FBS). Differentiation and fusion into multinucleated
myotubes was induced at 70% conﬂuence by replacing skeletal
muscle growth medium with serum-reduced fusion medium
(Dulbecco’s modiﬁed Eagle’s medium supplemented with 2% horse
serum and 2mM glutamine) for 6 days. All cells were analysed by
in vivo
35S-metabolic labelling studies (Chomyn et al., 1996), high-
resolution northern blot analysis (Tuppen et al., 2008) and immuno-
blotting as described.
In vivo labelling and analysis of
mitochondrial protein synthesis
In vivo
35S-metabolic labelling studies were performed as described
previously (Chomyn et al., 1996) with the following modiﬁcations.
Cells, cultured to 60–70% conﬂuency in T25mm ﬂasks, were pre-
treated with Dulbecco’s modiﬁed Eagle’s medium (DMEM; Sigma,
Poole, UK) containing 10% (v/v) FBS, 50mg/ml uridine and
50mg/ml chloramphenicol for 15h at 37 C/5% CO2. Cells were sub-
sequently washed with phosphate-buffered saline (PBS; Sigma, Poole,
UK) and incubated for 15min at 37 C/5% CO2 in methionine/
cysteine and FBS-free DMEM, supplemented with 5% (v/v) dialysed
FBS, 0.1mg/ml anisomycin (Sigma, Poole, UK). Following addition of
200mCi/ml
35S-methionine/cysteine (
35S EasyTag EXPRESS; Perkin
Elmer, Beaconsﬁeld, UK), cells were incubated for 2h at 37 C/5%
CO2, then washed with PBS and a cell pellet was prepared. Total
protein yield was calculated by Bradford assay and equal quantities
of total protein (50mg) were pretreated with 1U Benzonase
Endonuclease (Merck & Co., Inc, New Jersey, USA) for 1h.
Pretreated samples were then separated by sodium dodecyl sulphate
Table 1 Summary of the clinical presentation of reversible COX deﬁciency in 17 patients
Patient Affected relatives Onset Clinical presentation Improved Last control Reference
Muscle Ventilation Tube
feeding
Liver
P1/M – 36h + + + – 5–16months 33months mild
myopathy
DiMauro,
1983
P2/M – 6 weeks + + + – 6–15months 20months mild
myopathy
Zeviani,
1987
P3/M Sibling (P4) 3 weeks + + + + 5–20months 4 years healthy Salo, 1992
P4/F Sibling (P3) 12 weeks + – + – From 6months 13months mild
myopathy
Salo, 1992
P5/F Sibling 24 days + + + – None Died at 39 days This article
P6/F – 4 weeks + + + – 7–12months 7.5 years myopathy,
epilepsy
This article
P7/M
a 15 days + + + – 5months 22months stands with
support
This article
P8/M – Birth + – – – 4months 5 years normal This article
P9/M Maternal uncle (P10) 1 month + – + + 10–22months 22 years mild prox.
myopathy
Houshmand,
1994
P10/M Maternal nephew (P9) 1 month + + + – 7–18months 7 years healthy This article
P11/F – Birth + – + – 9–36months 17 years mild
myopathy
Houshmand,
1994
P12/M – 2 months + – + – 5–19months 7 years healthy This article
P13/F – 1 month + – + – 11–17months 11 years healthy This article
P14/M Sibling (P15), maternal sibs
(P17, P16)
Birth + + + + 6–30months 11 years mild
myopathy
This article
P15/M Sibling (P14), maternal sibs
(P17, P16)
2.5 months + + + – 5–20months 9 years healthy This article
P16/F Sibling (P17), maternal
nephews (P14,15)
1 month + – + – 6–24months 26 years healthy This article
P17/M Sibling (P16), maternal
nephews (P14, 15)
1 month + – + – 5–18months 26 years healthy This article
a Mild motor developmental delay in the mother, disturbed weight gain and anaemia in one sibling.
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were visualized by PhosphorImager analysis (Amersham Biosciences,
Little Chalfont, UK) and equal protein loading was conﬁrmed by
Coomassie blue staining.
Results
Clinical presentation
The disease affects skeletal muscle selectively and in a strictly age-
speciﬁc manner, since all patients had profound hypotonia,
respiratory and feeding difﬁculties in the ﬁrst days or weeks of
life, together with highly increased serum lactate. One patient
died of pneumonia at 39 days as a consequence of the severe
muscular hypotonia and respiratory insufﬁciency, but all others
improved spontaneously between 4 and 20 months of age
(Table 1). However, a mild residual myopathy frequently persisted
later in life (Fig. 1). Some children showed mild, reversible involve-
ment of other organs (liver, heart), but only during the most
severe metabolic crises, when increased CK and low carnitine
levels were also found occasionally (Table 2). Brain, peripheral
nerves and cognitive development were unaffected in all patients
in the initial phase of the disease, although Patient 6 developed
neurological symptoms at a later stage. Family history suggested
maternal inheritance in three families (Fig. 1) and siblings were
affected in three families without parental consanguinity.
Muscle histology and biochemistry
The ﬁrst muscle biopsy was performed in all children in the acute
phase of the disease (1–5 months of age). In seven patients,
follow-up biopsies were also obtained (Table 2). In summary,
early biopsies conﬁrmed severe mitochondrial myopathy with
RRF and even more numerous COX-negative ﬁbres and ultrastruc-
turally abnormal mitochondria in all patients. These changes sig-
niﬁcantly improved, but usually did not completely disappear on
later biopsies (Fig. 2). On routine morphology, many muscle ﬁbres
appeared normal but vacuolar changes and mild structural
abnormalities with lipid and/or glycogen accumulation were
detected in most cases. Electron microscopy was performed in
four patients and showed giant mitochondria with very character-
istic multilamellar paracrystalline inclusions.
Biochemical analysis of RC enzymes in muscle revealed com-
bined RC deﬁciencies, most severely affecting COX in early biop-
sies (Table 2). This was accompanied by a defect of complex I
and, less commonly, of other complexes containing mtDNA-
encoded subunits. In the recovery phase, all RC activities returned
to normal or supernormal levels, indicating the involvement of
compensatory mechanisms.
Molecular genetic analysis
Molecular genetic analysis revealed no mtDNA deletions and
normal mtDNA copy number in muscle from all patients tested
and there were no signiﬁcant differences between follow-up biop-
sies. Sequencing of the entire mitochondrial genome revealed sev-
eral nucleotide variations from the revised Cambridge reference
sequence, represented on publicly available databases (http://
www.mitomap.org/; http://www.genpat.uu.se/mtDB/). A single
homoplasmic variant, m.14674T4C (Fig. 4A), was detected in all
17 patients and in all maternal family members (Fig. 1). The muta-
tion analysis in the relatives of the probands was performed in
DNA extracted from blood leukocytes. This mutation affects a
poorly conserved nucleotide, but we could not detect it in 200
German control individuals. It is reported in 3 out of 2704 samples
in both the mtDB and the MITOMAP databases as a neutral
polymorphism labelled haplogroup M27b, although retrospective
analysis of the subjects listed in MITOMAP revealed that these
individuals did in fact present with a clinical phenotype similar to
that reported here (Patients 9 and 11 in this study) (Houshmand
et al., 1994). The patients belong to different major mtDNA hap-
logroups (H, U, V).
High-resolution northern blot analysis
Northern blotting of skeletal muscle of Patients 7, 11 and 14 and
primary cell cultures of Patients 7 and 14 indicated that the
steady-state level of mt-tRNA
Glu was signiﬁcantly decreased com-
pared to controls (Fig. 3A). The decrease was most severe
(16–30% of age-matched controls) in skeletal muscle taken at
1–3 months of age. The steady-state level of the mt-tRNA
Glu in
the second muscle biopsy after recovery and also in clinically
healthy mothers of Patients 7 and 11 was less severely decreased
(30–60%) and similar to that detected in myoblasts.
Immunoblotting
Immunoblotting with monoclonal antibodies against mitochondrial
-encoded COX and complex I subunits showed markedly
decreased levels in early biopsies, when the children showed
severe symptoms, but were normal in biopsies after recovery
and in healthy mothers (Fig. 3B).
In vivo labelling and analysis of
mitochondrial protein synthesis
Pulse labelling experiments with
35S methionine in myoblasts of
Patients 14 and 7 showed normal intensity for most mitochondrial
proteins (Fig. 4B). Immunoblotting with antibodies against mito-
chondrial proteins conﬁrmed the normal (or increased) levels of
COX and complex I subunits in the patient’s cells (Fig. 3B).
Further evidence for the rescue in vitro is provided by the
normal RC activities on direct enzyme measurement. These
ﬁndings were unexpected because the steady-state level of
mt-tRNA
Glu was still low (50% of controls).
Discussion
The homoplasmic m.14674T4C mutation was detected in
17 affected individuals from 12 independent families of different
ethnic origins. The different mtDNA haplogroup backgrounds indi-
cate that the same mt-tRNA
Glu mutation has arisen independently,
3168 | Brain 2009: 132; 3165–3174 R. Horvath et al.on multiple occasions, causing the same disease. Seven out of 22
maternal family members from three families (Fig. 1) developed
severe, mostly isolated muscle hypotonia and weakness requiring
intensive care, but most homoplasmic carriers never experienced
muscle weakness. The penetrance of the disease is variable, as
seen in other mtDNA mutations, but the strong association with
the phenotype and the reduced levels of mt-tRNA
Glu transcript
observed in the biopsies are highly suggestive of a pathogenic link.
This is also the case for other homoplasmic mtDNA mutations,
as in Leber’s hereditary optic neuropathy (LHON) (Yu-Wai-Man
et al., 2009). In LHON, the variable penetrance was attributed to
the modifying role of nuclear factors, to mtDNA background, and
Mip1C
Patient 7
II:1
P9
I:1 I:2
II:2 II:3
III:1
P10
II:1 II:2
III:1
P14
III:2
P15
I:1 I:2
II:3 II:4
P16
II:5
P17
II:7 II:8 II:9
III:3
Patients 14-17
I:1 I:2
II:1 II:2 II:3 II:4 II:5 II:6 II:8
P7
II:9
182
108
74
46
26
U  P14 P15 P16 P17 II:2 II:3 II:7  II:1  II:7  II:8  I:2
RFLP for m.14674T>C 
II:2 III:2 III:3
III:2
Patients 9, 10
II:4 III:1
III:1
Figure 1 Pedigrees of three families suggested a maternal inheritance. RFLP analysis for m.14674T4C in the family of Patient 14
revealed that the mutation is homoplasmic in all maternal individuals and absent in the fathers. The two brothers, at ages 8 and 10
years, showed signs of a mild residual myopathy. P14 (III:1) has a myopathic face and both patients (III:1, III:2) show scapular winging.
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mechanisms are likely to underlie the manifestation of reversible
COX deﬁciency myopathy. To identify other potential modiﬁers, a
better understanding of the disease pathogenesis is required,
although we were not able to deﬁne any epistatic, epigenetic or
environmental modifying factors in the 17 cases studied here.
What is the pathological mechanism
of the disease?
To date, six pathogenic mutations have been described in mt-
tRNA
Glu (http://www.mitomap.org/), all of which tend to reach
either a very high level of heteroplasmy or homoplasmy in the
skeletal muscle of affected individuals. Although the clinical
phenotype is variable, there is constant and predominant involve-
ment of skeletal muscle. However, none of these patients had a
truly reversible phenotype, implying that reversible COX deﬁciency
myopathy is not a generic consequence of mutations in mt-
tRNA
Glu, but speciﬁcally of m.14674T4C.
This mutation affects the discriminator base of mt-tRNA
Glu. This
is the last base at the 30-end of the molecule, where the amino
acid is attached to the molecule via the terminal CCA. No patho-
genic mutation has previously been described in this crucial posi-
tion in any of the other 21 mitochondrial transfer RNAs.
The m.14674T4C mutation in mt-tRNA
Glu is thought to impair
mitochondrial translation, as reﬂected by the RRF/COX-negative
ﬁbres and the multiple RC defects in skeletal muscle. The predo-
minant involvement of the mitochondrial COX subunits (Tritschler
et al., 1991) may be explained by their high glutamic acid content
or by the locations of the glutamic acid residues. The expression of
stable mt-tRNAs relies on a number of post-transcriptional mod-
iﬁcation steps including: (i) 50 and 30 processing from the large
polycistronic transcript by mitochondrial RNaseP (and presumably
by tRNase Z); (ii) addition of the CCA trinucleotide to the 30-end
of the mt-tRNA transcript by [CCA] nucleotidyltransferase;
Table 2 Laboratory investigations and muscle biopsy ﬁndings of 17 patients with reversible COX deﬁciency
Patient Laboratory results Muscle histology EM RC
Lactate CK Carn RRF/COX– Lipid Glycogen Other ﬁndings COX Other RC
P1 """ Norm 1 month: +++ + – Normal 6% Norm
7 months: ++ ++ + Few atrophic ﬁbres Giant mt, crista path 50% Norm
36 months: – – – Fibrosis, atrophy " Norm
P2 """ " 662 # 2 months: +++ + – Normal n.d. n.d.
4 months: +++ + + Normal 11% Norm
11 month: – – – Fibrosis, atrophy 57% Norm
P3 """ "" 1402 ## 3 months: +++ + + Necrotic/split ﬁbres Giant mt, crista path 25% Norm
16 months: – – – Normal n.d. n.d.
P4 """ " 798 # 3 months: +++ + + Necrotic/split ﬁbres 25% Norm
13 months: + – – Mild myopathy n.d. n.d.
P5 """ n.d. 1 month: +++ + – Normal n.d. n.d.
P6 """ 119 # 1 month: ++ + – Vacuolar myopathy 29% Norm
P7 """ Mild" 3 months: +++ + + Normal 29% Norm
13 months: normal – – Normal 121% Norm
P8 """ n.d. 5 months: +++ + – Normal 52% Norm
P9 """ " 2 months: +++ + – Abnormal mt ### CI ###
5 years 4 months: + – – Mild myopathy Norm CI #
14 years 5 months: + – – Necrotic/mild myopathy # CI #
P10 """ Norm 1 month: +++ – – Normal ### CI ###
P11 """ " 1 month: +++ + – Abnormal mt ### CI ###
8 years 9 months: + –– Mild myopathy Norm Norm
P12 "" " # 3 months: +++ – – Normal ### CI ##
P13 """ " 1 month: +++ – – Normal n.d. n.d.
P14 """ Norm # 1 month: +++ + + Abnormal mt Giant mt, crista path 5% CI 25%
10 years: + –– Normal 110% Norm
P15 """ Norm 1 month: +++ + + Abnormal mt Giant mt, crista path 3% CI 15%
P16 """ Norm n.d. n.d. n.d. n.d. n.d. n.d. n.d.
P17 """ Norm n.d. n.d. n.d. n.d. n.d. n.d. n.d.
+++=severe (425%); ++=moderate (5%–25%); +=mild (55%); """=severely increased; ""=moderately increased; "=mildly increased; CI=complex I; mt=mi-
tochondria; n.d=no data.
3170 | Brain 2009: 132; 3165–3174 R. Horvath et al.base modiﬁcation by a variety of mt-tRNA modifying enzymes;
and (iii) aminoacylation of mt-tRNA by the cognate aminoacyl
mt-tRNA synthetase (Levinger et al., 2004). It had been shown
that mutations in the proximity of a discriminator base affect RNA
processing (Levinger et al., 2004), but we are not aware of any
functional data on mutations affecting the discriminator base itself,
and northern blot analysis gave no indication of unprocessed inter-
mediates in our patients’ samples. As a consequence of the muta-
tion, the steady-state level of mt-tRNA
Glu was decreased in
skeletal muscle from three patients (Fig. 3A). Counter intuitively,
the steady-state level of mt-tRNA
Glu showed only a slight increase
in the follow-up muscle biopsy, when the children were almost
asymptomatic, and remained low (30–60%) in cells from
patients and in muscle from clinically healthy mothers. The slight
recovery of the steady-state level of mt-tRNA
Glu in the face of
dramatic clinical improvement indicates that either this mild
increase of mt-tRNA
Glu steady-state level is sufﬁcient to regain
normal mitochondrial translation, or that other mechanisms down-
stream of mt-tRNA
Glu explain the clinical and biochemical
improvement in vivo. Concerning the apparent surplus of mt-
tRNA, it is interesting to note that normal levels of mitochondrial
translation can be maintained by surprisingly low steady-state
levels ( 10%) of the homoplasmic mt-tRNA
Val, m.1624C4Ta t
least in cultured myoblasts, ﬁbroblasts and transmitochondrial
cybrids (Rorbach et al., 2008).
In vitro pulse-labelling experiments in two patients (7 and 14)
showed normal mitochondrial translation in myoblasts compared
to normal controls (Fig. 4B). This result was bolstered by
* *
B A
C D
E F
Figure 2 Histochemical staining of the muscle biopsy from Patient 7at 3 months of age (A and B) and 9 years (C and D) and of the
muscle from his asymptomatic mother (E and F). The early biopsy conﬁrmed severe mitochondrial myopathy with RRF (A) and even
more COX-negative ﬁbres (B). These changes signiﬁcantly improved but did not completely disappear at 9 years of age (C and D). The
muscle biopsy from the mother revealed a few COX-negative (F), SDH hyper-reactive (E) ﬁbres (stars). A, C: Gomori trichrome; B, D, F:
COX; E: SDH stain. Magniﬁcation: A, B 100 , C, D, E, F 200 .
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for mtDNA-encoded proteins (Fig. 3B) and by the normal RC
enzyme activities. Experiments on cybrid cells would not have
been informative, since cells homoplasmic for the mt-tRNA muta-
tion do not display a clear biochemical defect. It is worth noting
again that the same cells showed 40–50% decreased mt-tRNA
Glu
steady-state levels.
Why do symptoms start in early
neonatal life and what is the
mechanism of the spontaneous
recovery?
Although our data provide strong evidence for a pathogenic role
of m.14674T4C, they do not explain why all patients develop
severe isolated myopathy in the neonatal period and, most impor-
tantly, what triggers the timed spontaneous recovery. We suggest
that tissue-speciﬁc, developmentally timed processes play a role
both in the age-dependent expression and in the reversibility.
One hypothesis is that an increase in mtDNA copy number and
the consequent increase in the number of tRNA
Glu molecules
would compensate for the defect and may overcome the func-
tional consequences of the homoplasmic tRNA mutation in skeletal
muscle. Morten et al. (2007) showed that the mtDNA content of
liver increases rapidly over the perinatal period up to 1 year of
age. In muscle, a similar progressive increase in mtDNA copy
number, RC activity, and muscle power was also detected.
Comparative studies of muscle mtDNA from 54 patients showed
that patients 7–12 months of age had slightly higher mtDNA copy
number than patients56 months of age (Macmillan et al., 1996),
but the increase was not statistically signiﬁcant. Another study on
300 muscle DNA samples showed that mtDNA content in muscle
increases steadily from birth to about 5 years of age (Bai et al.,
2004). We measured mtDNA copy numbers in muscle DNA
extracted from consecutive biopsies but did not get any signiﬁcant
changes compared to normal controls, indicating that the recovery
in benign COX deﬁciency cannot be explained by a change in
mtDNA copy number.
Another explanation would relate the recovery to the modifying
effects of muscle-speciﬁc genes that are developmentally regu-
lated and display isoform switching. Many of these genes
encode contractile proteins or enzymes involved in energy metab-
olism. It was shown that the nuclear-encoded COXVIa and
C         C      C      P11
mt-tRNALeu(UUR)
mt-tRNAGlu
C        C C       M       P11
1         1       0.96 0.55 0.3 1        1      0.8 0.5
C       C       C      P14
Myoblasts Skeletal Muscle 
> 1 yr - adult 0-3 months 
Porin 39 kDa
CII-70      70 kDa
COXI        57 kDa
C        C       C     P11 C        C  C      P11     M C        C    C      P14
> 1 yr - adult 0-3 months  Myoblasts
COX II      25.5 kDa
NDUFB8   20 kDa
A   Northern blots
B  Immunoblotting
Figure 3 (A) Northern blot for mt-tRNA
Glu showed severely decreased steady-state levels in skeletal muscle of Patient 11at 1 month
of age and slightly higher, but still signiﬁcantly decreased levels, after clinical recovery at 9 years of age, as well as in muscle biopsies of
her asymptomatic mother (M). Data from skeletal muscle are not shown for Patients 7 and 14. Myoblasts of Patient 14 showed steady-
state levels similar to late biopsies and to biopsies of a healthy mother. Patient mt-tRNA
Glu steady-state levels normalized to
mt-tRNA
Leu(UUR) levels are expressed relative to normalized control levels. (B) Immunoblotting showed decreased levels of the mito-
chondrial COXI, COXII and complex I (NDUFB8) subunits in the biopsy of Patient 11at 1 month of age, which returned to normal at 9
years of age, and was also normal in her asymptomatic mother. The same subunits were slightly increased in myoblasts of Patient 14.
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development (Tritschler et al., 1991) and switch from foetal or
ubiquitous isoforms to the corresponding muscle isoforms as
development progresses. However, the exact timing of such
changes needs to be further evaluated. These data may also sup-
port a developmental switch in the control strength of mitochon-
drial transfer RNAs and, in particular, mt-tRNA
Glu in mitochondrial
translation, suggesting that 16–30% steady-state levels of mt-
tRNA
Glu may have a profound effect on translation in muscle of
neonates but may become less critical at later stages of
development.
In summary, we provide evidence that reversible COX deﬁ-
ciency myopathy is caused by a homoplasmic mt-tRNA
Glu muta-
tion m.14674T4C. This is critically important because severe
mitochondrial myopathy in early life is usually irreversible, prompt-
ing clinicians and parents to face end-of-life decisions for a young
child. We suggest that ﬂoppy infants with suspected mitochondrial
myopathy should be screened for this mutation. This simple
genetic test is of critical importance for prognosis and manage-
ment of these infants because the benign form is initially life
threatening but ultimately reversible.
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